Microalbumin Urine
MA
Description
"Microalbumin Urine" test detects small amounts of albumin in your urine, which can signal early kidney damage. It’s commonly recommended for people with diabetes or high blood pressure to catch signs of chronic kidney disease before symptoms appear. Elevated albumin levels may indicate your kidneys are under stress. Results help doctors intervene early through medications, lifestyle changes, or closer monitoring. Ongoing testing allows for personalized care and can slow the progression of kidney problems.
Test Category
Proteins
Procedure
Non-Invasive
Sample Type
Urine
Units
Milligrams Per 24 Hours | Milligrams Per Gram
Procedure Category
Collect, Measure
Test Group
Urine Test Group, Complete Kidney Group
Test Group Description
Complete Kidney Group: Comprehensive tests provide a thorough assessment of kidney function, yielding detailed insights into renal health and associated conditions. Urine Test Group: It encompasses a variety of tests aimed at evaluating urinary composition, protein levels, microscopic abnormalities, and microbial cultures, offering comprehensive insights into urinary health and potential related conditions.
Optimal Range
For All Individuals:
Conventional Unit: 24-hour Collection: <20.00 mg/24 hr | ACR (Albumin-to-Creatinine Ratio): <20.0 mg/g
SI Unit: Not Applicable
Normal Range
For All Individuals:
Conventional Unit: 24-hour Collection: <30.00 mg/24 hr | ACR (Albumin-to-Creatinine Ratio): <30.0 mg/g
SI Unit: Not Applicable
Results That Differ From The Norm (Direct and Indirect Causes)
Increased levels may indicate:
Atherosclerosis (Build-up of plaque in arteries)
Chronic kidney disease
Glomerulonephritis (Inflammation of the kidney's filtering units)
Heart failure (Inability of the heart to pump blood effectively)
Hypertension (High blood pressure)
Obesity
Polycystic kidney disease (Genetic disorder causing fluid-filled cysts in the kidneys)
Systemic lupus erythematosus (Autoimmune disease affecting multiple organs)
Type 2 Diabetes (High blood sugar levels)
Urinary tract infections
Key Reasons For Testing
Early Detection of Kidney Damage: Identifies kidney issues in individuals with diabetes or hypertension before significant dysfunction occurs.
Assessment of Diabetic Nephropathy: Evaluates risk and progression of kidney damage in diabetes.
Prediction of Cardiovascular Risk: Serves as a marker for heart attack and stroke risk.
Monitoring of Hypertensive Patients: Detects kidney and cardiovascular risks in hypertensive individuals.
Evaluation of CKD: Assesses renal function and disease progression in chronic kidney disease.
Health Status Conditions It May Be Used To Assess
Currently, this test is not directly associated with any conditions listed on the Health Status page. However, it may be included as part of a broader set of tests linked to specific health conditions.
Some Prominent Medical Labs That May Offer This Test
Please note that this particular test has not been associated with any of the listed prominent medical labs. We recommend enquiring with your private physician or nearest hospital to determine where this specific test can be performed.
References
Important Note
Any medical procedure yielding results outside the norm may be directly or indirectly linked to the conditions outlined on this page. Various factors, including genetics, medication and supplement usage, recent illnesses, pregnancy, pre-test eating, smoking, and stress, can impact the test's outcome. Additionally, factors like false positives, false negatives, inaccurate analyses, and others can influence results.
Reference ranges, which help healthcare professionals interpret medical tests, may vary depending on age, gender, and other factors. They may also differ between laboratories due to variations in instruments and methods used. Optimal ranges are designed for preventive purposes, aiming to identify trends and potential risks early, while normal ranges reflect conventional laboratory values indicating no current disease or pathology. Your healthcare practitioner may have specific reasons for testing that deviate from the usual or may interpret results differently based on individual circumstances. Proper interpretation typically involves considering clinical findings and other diagnostic tests. Hence, it is crucial to provide your healthcare professionals with a comprehensive medical history, consult with them for result interpretation, and follow their guidance for potential re-testing or additional diagnostics.
Disclaimer
This content is provided solely for informative and educational purposes. It is not intended as a substitute for medical advice or treatment from a personal physician. Regarding the interpretation of their medical test results and/or specific health questions, it is recommended that all readers and viewers consult their physicians or other qualified health professionals. The publisher is not responsible for any adverse health effects that may result from reading or following the information in this educational content. Before beginning any nutrition, supplement, or lifestyle program, all viewers, especially those taking prescription or over-the-counter medications, should consult their physician or health care practitioner.
Please note that while prominent lab names are included in this content, we cannot guarantee that these labs offer all the tests mentioned. For confirmation, individuals should contact the labs directly or consult their medical practitioners. The information provided reflects general knowledge at the time of publication and may not include recent updates or emerging research. Readers should verify details with qualified professionals to ensure the most up-to-date and accurate guidance.
[1] Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med. 1984;310(6):356-360.
[2] Viberti GC, Hill RD, Jarrett RJ, Argyropoulos A, Mahmud U, Keen H. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet. 1982;1(8287):1430-1432.
[3] Parving HH, Hovind P, Lehnert H, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001;345(12):870-878.
[4] De Jong PE, Curhan GC. Screening, monitoring, and treatment of albuminuria: Public health perspectives. J Am Soc Nephrol. 2006;17(8):2120-2126.
[5] Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes. 2002;51(4):1157-1165.
[6] Ruggenenti P, Perna A, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet. 1998;352(9136):1252-1256.
[7] Heerspink HJ, Gansevoort RT, Brenner BM, et al. Comparison of different measures of urinary protein excretion for prediction of renal events. J Am Soc Nephrol. 2010;21(8):1355-1360.
[8] Klausen KP, Scharling H, Jensen G, Jensen JS. New definition of microalbuminuria in hypertensive subjects: association with incident coronary heart disease and death. Hypertension. 2005;46(1):33-37.
[9] Sacks DB, Arnold M, Bakris GL, et al. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. Clin Chem. 2011;57(6).
[10] Damsgaard EM, Froland A, Jorgensen OD, Mogensen CE. Microalbuminuria as predictor of increased mortality in elderly people. BMJ. 1990;300(6720):297-300.
[11] Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. N Engl J Med. 2003;348(23):2285-2293.
[12] Jerums G, Panagiotopoulos S, Premaratne E, MacIsaac RJ. Integrating albuminuria and GFR in the assessment of diabetic nephropathy. Nat Rev Nephrol. 2009;5(8):397-406.
[13] Witte EC, Lambers Heerspink HJ, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT. First morning voids are more reliable than spot urine samples to assess microalbuminuria. J Am Soc Nephrol. 2009;20(2):436-443.
[14] Ruggenenti P, Fassi A, Ilieva AP, et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med. 2004;351(19):1941-1951.